bcd-085
mAbexperimental
Clinical trial activity
7 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
6
Phase 3
3
Phase 4
0
Earliest trial started Mar 1, 2015 (NCT02380287)
Timeline
Indications
Mechanism of action
- Interleukin-17 receptor AINHIBITOR
IL17RA inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- bcd-085
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03598751 | Phase 3 | Sep 10, 2018 | Biocad |
| NCT03476993 | Phase 2 | Apr 27, 2018 | Biocad, Moscow State University |
| NCT03447704 | Phase 3 | Feb 8, 2018 | Biocad |
| NCT03390101 | Phase 3 | Dec 20, 2017 | Biocad |
| NCT02763111 | Phase 2 | Sep 1, 2016 | Biocad |
| NCT02762994 | Phase 2 | Jun 1, 2016 | Biocad |
| NCT02380287 | Phase 1 | Mar 1, 2015 | Biocad |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Biocad | For profit | 7 | 7 | 3 | 2015 |
| Moscow State University | Academic/Hospital | 1 | 0 | 1 | 2018 |
2 organizations
Page 1 / 1